Latest News Archive

Please select Category, Year, and then Month to display items

Three Kovsies in Springbok coaching team

31 January 2020 | Story Ruan Bruwer | Photo Gallo Images

The appointment of Jacques Nienaber as the new Springbok head coach means that a former Kovsie will once again coach the Springbok team. Nienaber takes over from Rassie Erasmus, another Kovsie alumnus.

It was also announced that Daan Human, like Erasmus a former Shimla player who went on to play for the Springboks, will be the scrum consultant. Erasmus will continue in the role of director of rugby and will be part of the Springbok coaching team, which means that half of the six coaches in the team can call themselves Kovsies.

Nienaber joined Erasmus in the Springbok coaching team in February 2018 as defensive coach. At the 2019 Rugby World Cup, the Springboks conceded the fewest tries (four) of all the teams. Erasmus will be responsible for the strategy and results, with Nienaber taking operational control.

It will be the first time Nienaber steps into a head-coach role. He started as physiotherapist with the Shimlas U20 team, before going into strength and conditioning and later becoming a defence coach.“This is a massive honour and responsibility, but I think I have a good understanding of what it entails, especially in this new structure. It’s a big step-up for me. I would not have accepted if I didn’t believe I could be successful,” said the 47-year-old Nienaber.

“I’ve been worked with Rassie in a coaching capacity for nearly two decades now and we have a very good idea of how each of us thinks.” The two first worked together in the Shimlas U20 team, where Erasmus was the captain and Nienaber the physio.

Besides Nienaber, two other former Shimlas are currently in a head-coach role – Neil Powell at the Springbok Sevens team and Franco Smith is coaching the Italian national team.

News Archive

New research informs improved treatment of brain inflammation

2017-10-13

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish

Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology.

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs.

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept